QT VASCULAR LTD.
(Company Registration No. 201305911K)
(Incorporated in Singapore)
("**Company**")

ANGIOSCORE LITIGATION
- UPDATE

1. Reference is made to the earlier announcement and media statement of the Company dated 29 April 2015 and 4 May 2015, respectively, on the AngioScore litigation. Capitalised terms herein shall have the same meanings ascribed in the aforesaid announcement.

   The Board of Directors of the Company would like to provide the following updates in relation to the State Law Claims:

State Law Claims

2. Subsequent to the close of the trial phase for the State Law Claims, the trial court in California has on 1 July 2015 issued its findings of facts and conclusions of law, and awarded damages of US$20.034 million against Dr. Konstantino, TriReme Medical LLC, Quattro Vascular Pte. Ltd., and QT Vascular Ltd. (collectively "**Defendants**").

3. The Defendants are obviously disappointed with the trial court's decision. Together with their US counsel, they have carefully studied the trial court's decision, and respectfully and vigorously disagree with the trial court.

4. The Defendants fully intend to file an appeal, to challenge and overturn the trial court's decision, once judgment has been entered by the trial court. The judgment is expected to be entered in the later part of this year.

5. As part of the appeal, the Defendants expect to mount a strong and robust rebuttal against the trial court's decision on meritorious grounds in due course. Pending the results of such appeal, the Defendants do not have to make any payments to AngioScore.

6. More pleasingly, as part of its findings of facts and conclusions of law, the trial court has denied AngioScore's application for an injunction to enjoin the sale of Chocolate® by the Group. Accordingly, defendants can continue to sell Chocolate® without any interruption from AngioScore.

Further Updates

7. The Company will continue to keep shareholders informed of material developments in the ongoing litigations.

8. In the meantime, shareholders should exercise caution in trading of the Company's shares, and where they have any doubts, should consult their professional advisers accordingly.

By Order of the Board
QT VASCULAR LTD.

Eitan Konstantino
Chief Executive Officer
2 July 2015

*The Company was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") on 29 April 2014. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**").*

This announcement has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not independently verified the contents of this announcement.

This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assumes no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made, or reports contained in this announcement.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone (65) 6229 8088.